Outcomes and endpoints in cancer trials: Bridging the divide

Michelle K. Wilson, Deborah Collyar, Diana T. Chingos, Michael Friedlander, Tony W. Ho, Katherine Karakasis, Stan Kaye, Mahesh K.B. Parmar, Matthew R. Sydes, Ian F. Tannock, Amit M. Oza

Research output: Contribution to journalReview articlepeer-review

Abstract

Cancer is not one disease. Outcomes and endpoints in trials should incorporate the therapeutic modality and cancer type because these factors affect clinician and patient expectations. In this Review, we discuss how to: define the importance of endpoints; make endpoints understandable to patients; improve the use of patient-reported outcomes; advance endpoints to parallel changes in trial design and therapeutic interventions; and integrate these improvements into trials and practice. Endpoints need to reflect benefit to patients, and show that changes in tumour size either in absolute terms (response and progression) or relative to control (progression) are clinically relevant. Improvements in trial design should be accompanied by improvements in available endpoints. Stakeholders need to come together to determine the best approach for research that ensures accountability and optimises the use of available resources.

Original languageEnglish (US)
Pages (from-to)e43-e52
JournalThe Lancet Oncology
Volume16
Issue number1
DOIs
StatePublished - Jan 1 2015

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Outcomes and endpoints in cancer trials: Bridging the divide'. Together they form a unique fingerprint.

Cite this